Compare · DFTX vs TLRY
DFTX vs TLRY
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Tilray Brands Inc. (TLRY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and TLRY operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $6.02B, about 10.6x TLRY ($568.6M).
- Both names hit the wire about 15 times in the past 4 weeks.
- TLRY has more recent analyst coverage (14 ratings vs 7 for DFTX).
- Company
- Definium Therapeutics Inc.
- Tilray Brands Inc.
- Price
- $44.77+3.55%
- $4.89+3.49%
- Market cap
- $6.02B
- $568.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 15
- 15
- Recent ratings
- 7
- 14
Tilray Brands Inc.
Tilray, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. It provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products. The company offers its products to retailers, wholesalers, patients, physicians, pharmacies, clinics, hospitals, governments, and researchers. It has operations in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company was formerly known as Aphria Inc. Tilray, Inc. was incorporated in 2018 and is based in New York, New York.
Latest DFTX
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Latest TLRY
- BrewDog Wins Big at the 2026 World Beer Awards with a Sweeping Show of Brewing Excellence
- Tilray Strengthens Global Medical Cannabis Leadership with Major Production Increase to Meet International Demand
- BrewDog Unwraps Its 2026 Advent Calendar
- Tilray Medical Welcomes Progress in Germany’s Medical Cannabis Framework and Supports Continued Policy Development
- Montauk Brewing Company Expands Its Coastal Footprint with New North Shore Brewpub
- Tilray Medical Accelerates the Commercial Expansion of Tilray Medical-Branded Cannabis Medicines in the UK with First Direct-to-Patient Launch Through Lyphe Clinic and Lyphe Dispensary
- Montauk Brewing Company Announces New Collaboration with Morning Brew Inc.
- Hi*Ball® Energy Powers into the English Football League with Wolverhampton Wanderers Partnership
- Breckenridge Distillery Turns Colorado’s Famous Palisade Peaches into a Fresh Pour of Summer with New Peach Whiskey
- Tilray Brands Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities